The short version of clinical development fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Vernon Bogdanor (born 16 July 1943); author, academic, scholar, political scientist, historian, and research professor at the Institute for Contemporary British History at King's College London; emeritus professor of politics and government at the University of Oxford and an emeritus fellow of Brasenose College, Oxford; appointed Commander of the Order of the British Empire (CBE) in the 1998 Birthday Honours for services to constitutional history; appointed a Chevalier de la Légion d'honneur by president of France, Nicolas Sarkozy; was knighted in 2023 New Year Honours for services to political science. David Bohm (20 December 1917 – 27 October 1992) American British scientist and prolific author described as one of the most significant theoretical physicists of the 20th century, who contributed unorthodox ideas to quantum theory, neuropsychology and the philosophy of mind, of Hungarian Jewish origin. Alain de Botton popular author, broadcaster and YouTube channel entrepreneur, of Ashkenazi and Sephardic ancestry. He co-founded The School of Life. Botton is the son of Gilbert de Botton and descended from a distinguished Sephardic Jewish family; among his ancestors were the rabbinical scholar Abraham de Boton and Yolande Harmer journalist and Israeli intelligence officer.
== Treatment == According to the 2024 European Society of Coloproctology (ESCP) Guidelines published in BJS, treatment techniques for PSD include drainage and curettage, phenol application, fibrin glue, laser therapy, marsupialisation, EPSiT, minimally invasive surgery (MIS), pit picking, PRP, and excision with open healing. If there is an infection, treatment is generally by incision and drainage just off the midline because incisions in the midline have a hard time healing well. Following five simple rules has been known to prevent recurring inflammations for some people and avoid surgery: 1. Avoiding chairs and car seats that put pressure on the coccyx; 2. Being of average weight, preferably with low BMI; 3. Keeping the area clean; 4. Keeping the area dry by wearing exclusively cotton garments; 5. Keeping the area completely hair-free, for example, by regularly using an IPL hair removal device. The evidence for elective treatment of pilonidal sinus disease is poor. The most commonly performed surgery is for the pilonidal sinus complex to be surgically excised with the wound often left open to heal. Post-surgical wound packing may be necessary, and packing typically must be replaced daily for four to eight weeks. In some cases, two years may be required for complete granulation to occur. Sometimes the cyst is resolved via surgical marsupialization.
=== Bleeding lance === The bleeding lance has taken numerous forms throughout the Arthurian literature. In the earlier appearances of the lance, it is not represented as a Christian symbol, but transforms into one over time. In its early appearances in Perceval and Parzival, the lance is described as having "barbaric properties" which are difficult to associate with Christian influence. Chrétien describes his lance with "marvelous destructive powers", which holds a closer connection to the malignant weapons of Celtic origin. In Chrétien's Perceval, the lance is a dark and almost evil motif and also seems to overshadow the Grail, which, were this a Christian story, would be rather odd. Wolfram's tale also treated the lance in a similar dark manner. In Parzival, the lance is "poisonous" which contrasts sharply with the general trend of healing Christian themes. This lance is plunged into the Fisher King's wound at different times to continue his pain, as punishment for having sought forbidden love. This lance is considered significant because it is most often associated directly with the wound of the Fisher King, which is demonstrated both in Chrétien's and Eschenbach's versions of the tale. The more recent writings have the lance presented in the Fisher King's castle with Christian theology. More specifically, it is supposed to be the lance that pierced Jesus Christ while on the cross. This is seen in Malory's Le Morte d'Arthur. In Malory's version, the Fisher King is healed with the blood from the lance, signifying it as a good, holy, Christian object.
The BBC tells Gary Lineker he cannot present BBC One's Match of the Day until an agreement can be reached over his social media use. COVID-19 in the UK: Office for National Statistics data for the week ending 28 February indicates COVID-19 cases are rising in Scotland, but the picture is unclear in the rest of the UK. In England, the number of people testing positive for COVID-19 was estimated to be 1,333,400, equating to 2.38% of the population, or around 1 in 40 people. In Scotland, the figure was 128,400, equating to 2.44% of the population or around 1 in 40 people. 11 March The BBC apologises for 'limited' sports broadcasts, as a growing number of TV and radio presenters drop out of key programmes in support of Gary Lineker, amid an ongoing debate over impartiality. The Bank of England announces that the UK arm of Silicon Valley Bank is to enter insolvency, following the demise of its US parent, the largest banking collapse since the 2008 financial crisis. Many UK tech startups are prevented from accessing cash to pay staff. 12 March – The UK government announces that charges for prepayment energy meters are to be brought into line with those for customers paying by direct debit from 1 July, saving an average of £45 per year. 13 March HSBC agrees to buy the UK arm of Silicon Valley Bank, allowing UK tech firms and customers to access money and services as normal. Gary Lineker is allowed to return to presenting football, as the BBC announces an independent review of its social media guidelines.
=== Novel applications === Due to the versatility of SPR instrumentation, this technique pairs well with other approaches, leading to novel applications in various fields, such as biomedical and environmental studies. When coupled with nanotechnology, SPR biosensors can use nanoparticles as carriers for therapeutic implants. For instance, in the treatment of Alzheimer's disease, nanoparticles can be used to deliver therapeutic molecules in targeted ways. In general, SPR biosensing is demonstrating advantages over other approaches in the biomedical field due to this technique being label-free, lower in costs, applicable in point-of-care settings, and capable of producing faster results for smaller research cohorts. In the study of environmental pollutants, SPR instrumentation can be used as a replacement for former chromatography-based techniques. Current pollution research relies on chromatography to monitor increases in pollution in an ecosystem over time. When SPR instrumentation with a Kretschmann prism configuration was used in the detection of chlorophene, an emerging pollutant, it was demonstrated that SPR has similar precision and accuracy levels as chromatography techniques. Furthermore, SPR sensing surpasses chromatography techniques through its high-speed, straightforward analysis.
Sources: en.wikipedia.org
With somewhat less evidence, other studies have suggested that SCFRs may suppress the development and/or progression of human autism, schizophrenia, vascular dementia, strokes, pathological anxiety and depression disorders, behavioral and social communication disorders, and postoperative cognitive dysfunction. Some of these studies mention the possibility that SCFA-induced activation of FFAR2 suppresses these diseases and disorders but give no evidence to support this. The studies often do suggest that the SCFAs act by various other mechanisms to achieve their neurological effects. Furthermore, the role of SCFAs in humans with these diseases may be unclear. For example, two extensive reviews found that studies on the role of intestinal SCFAs in multiple sclerosis patients were inconclusive. There is a need to define the precise roles of SCFAs, FFAR2, and the other proposed causal factors in these neurological diseases and disorders.
After surgery, where the fascia has been incised and healing includes a scar that traverses the surrounding structures. Inflammatory diseases of the fascia, called Fasciitis Physical trauma, often injuries related sports or auto-collision Chronic psychomotor dysfunction, often driven by traumatic experiences, SMI, or SUD.
== Treatment == Treatment for AGAT and GAMT mainly consists of creatine supplementation. GAMT treatment may also include ornithine and sodium benzoate supplementation and/or diet restrictions in arginine and/or protein. These have shown to be effective, especially when started early in life. There is no current effective treatment for CTD. Creatine supplementation can have some benefit but because creatine does not easily pass the blood-brain barrier without a functioning transporter, neurological symptoms remain significant.
CAM plants, such as cacti and succulent plants, also use the enzyme PEP carboxylase to capture carbon dioxide, but only at night. Crassulacean acid metabolism allows plants to conduct most of their gas exchange in the cooler night-time air, sequestering carbon in 4-carbon sugars which can be released to the photosynthesizing cells during the day. This allows CAM plants to minimize water loss (transpiration) by maintaining closed stomata during the day. CAM plants usually display other water-saving characteristics, such as thick cuticles, stomata with small apertures, and typically lose around 1/3 of the amount of water per CO2 fixed.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.